Edition:
India

Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

4.91USD
1:30am IST
Change (% chg)

$0.26 (+5.59%)
Prev Close
$4.65
Open
$4.74
Day's High
$5.08
Day's Low
$4.70
Volume
273,390
Avg. Vol
403,616
52-wk High
$5.78
52-wk Low
$2.27

Latest Key Developments (Source: Significant Developments)

Amneal Launches Generic Fluphenazine Following ANDA Approval By FDA
Friday, 10 Jul 2020 

July 10 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL LAUNCHES GENERIC FLUPHENAZINE FOLLOWING ANDA APPROVAL BY FDA.AMNEAL LAUNCHES GENERIC FLUPHENAZINE FOLLOWING ANDA APPROVAL BY FDA.AMNEAL PHARMACEUTICALS INC - IMMEDIATELY INITIATED COMMERCIALIZATION ACTIVITIES ACROSS ALL DOSAGES.  Full Article

Amneal Reports Q1 Adjusted Earnings Per Share $0.20
Monday, 11 May 2020 

May 11 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $0.20.Q1 EARNINGS PER SHARE $0.78.Q1 REVENUE $499 MILLION VERSUS REFINITIV IBES ESTIMATE OF $446.1 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.09 -- REFINITIV IBES DATA.MAINTAINING 2020 FULL YEAR FINANCIAL OUTLOOK.  Full Article

Amneal Launches Generic Butrans Following ANDA Approval By FDA
Thursday, 16 Apr 2020 

April 16 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL LAUNCHES GENERIC BUTRANS® FOLLOWING ANDA APPROVAL BY FDA.  Full Article

Amneal Accelerates Production Of Hydroxychloroquine Sulfate
Saturday, 21 Mar 2020 

March 20 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ACCELERATES DISTRIBUTION AND PRODUCTION OF HYDROXYCHLOROQUINE SULFATE TO MEET POTENTIAL NEEDS OF COVID-19 PATIENTS NATIONWIDE.AMNEAL PHARMACEUTICALS - RAMPING UP PRODUCTION OF HYDROXYCHLOROQUINE SULFATE & EXPECTS TO PRODUCE ABOUT 20 MILLION TABLETS BETWEEN NOW & MID-APRIL.AMNEAL PHARMA - CO'S HYDROXYCHLOROQUINE SULFATE TABLETS APPROVED BY FDA TO TREAT MALARIA, RHEUMATOID ARTHRITIS, LUPUS, CHILDHOOD ARTHRITIS, OTHERS.  Full Article

Amneal Reports Q4 Adj. Earnings Per Share Of $0.08
Wednesday, 26 Feb 2020 

Feb 26 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 ADJUSTED EARNINGS PER SHARE $0.08.Q4 REVENUE $397 MILLION VERSUS REFINITIV IBES ESTIMATE OF $394.8 MILLION.Q4 LOSS PER SHARE $0.23.Q4 EARNINGS PER SHARE ESTIMATE $0.05 -- REFINITIV IBES DATA.SEES 2020 NET REVENUE BETWEEN $1,875 MILLION TO $1,975 MILLION.FY2020 REVENUE VIEW $1.70 BILLION -- REFINITIV IBES DATA.SEES 2020 ADJUSTED EPS $0.45 - $0.60.  Full Article

Amneal Receives Abbreviated New Drug Application Approval For Eluryng, The First Generic Nuvaring
Thursday, 12 Dec 2019 

Dec 12 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL RECEIVES ABBREVIATED NEW DRUG APPLICATION APPROVAL FOR ELURYNG™, THE FIRST GENERIC NUVARING®.AMNEAL PHARMACEUTICALS INC - HAS INITIATED COMMERCIALIZATION ACTIVITIES FOR ELURYNG.AMNEAL PHARMACEUTICALS - ANNOUNCES FDA APPROVAL OF ELURYNG, ONE OF 15 NEW PRODUCTS CO EXPECTS TO LAUNCH OVER NEXT 18 TO 24 MONTHS.  Full Article

Amneal To Acquire Majority Interest In AvKARE, Enhancing Access To Growing Federal Healthcare Market
Tuesday, 10 Dec 2019 

Dec 10 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL TO ACQUIRE MAJORITY INTEREST IN AVKARE, ENHANCING ACCESS TO GROWING FEDERAL HEALTHCARE MARKET.AMNEAL PHARMACEUTICALS INC - DEAL FOR IMPLIED ENTERPRISE VALUE OF $340 MILLION.AMNEAL PHARMACEUTICALS INC - FOLLOWING CLOSE OF TRANSACTION, AVKARE WILL OPERATE ON A STANDALONE BASIS AS AN INDEPENDENT SUBSIDIARY OF AMNEAL.AMNEAL PHARMACEUTICALS INC - AMNEAL WILL ACQUIRE A 65.1% MAJORITY INTEREST IN AVKARE.AMNEAL PHARMACEUTICALS - CONTRIBUTED ROLLOVER INTEREST WILL BE RETAINED BY SHIRLEY FAMILY, AVKARE'S FOUNDERS.AMNEAL PHARMACEUTICALS - SHIRLEY FAMILY WILL CONTINUE TO INDEPENDENTLY MANAGE OPERATIONS OF BUSINESS.AMNEAL PHARMACEUTICALS - CO TO PARTLY FINANCE PURCHASE OF AVKARE WITH A NEW $180 MILLION SENIOR SECURED TERM LOAN FACILITY.AMNEAL PHARMACEUTICALS - NEW DEBT FINANCING WILL BE SECURED BY NEWLY FORMED UNRESTRICTED SUBSIDIARY & WILL NOT IMPACT CO'S EXISTING TERM LOAN FACILITY.AMNEAL PHARMACEUTICALS INC - FOR TWELVE-MONTH PERIOD ENDED OCTOBER 31, 2019, AVKARE'S UNAUDITED CONSOLIDATED EBITDA WAS APPROXIMATELY $63 MILLION.AMNEAL PHARMACEUTICALS - ON A CONSOLIDATED BASIS, TRANSACTION IS EXPECTED TO REDUCE CO'S NET DEBT TO ADJUSTED EBITDA LEVERAGE RATIO.  Full Article

Amneal Pharmaceuticals Announces Approval And Launch Of Generic Carafate
Tuesday, 3 Dec 2019 

Dec 3 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES APPROVAL AND LAUNCH OF GENERIC CARAFATE.AMNEAL PHARMACEUTICALS INC - INITIATED GENERIC CARAFATE COMMERCIALIZATION ACTIVITIES..  Full Article

Amneal Announces Approval And Launch Of Generic Revatio For Oral Suspension And Generic Amicar Tablets
Tuesday, 3 Dec 2019 

Dec 2 (Reuters) - Amneal Pharmaceuticals Inc ::AMNEAL ANNOUNCES THE APPROVAL AND LAUNCH OF GENERIC REVATIO® FOR ORAL SUSPENSION AND GENERIC AMICAR® TABLETS.AMNEAL PHARMACEUTICALS - RECEIVED FINAL U.S. FDA APPROVAL ON ITS ABBREVIATED NEW DRUG APPLICATIONS FOR GENERIC VERSIONS OF REVATIO.AMNEAL PHARMACEUTICALS INC - HAS IMMEDIATELY INITIATED COMMERCIALIZATION ACTIVITIES.  Full Article

Amneal Enters Into A Licensing Agreement With Kashiv Biosciences, Llc To Develop And Commercialize K127 For The Treatment Of Myasthenia Gravis
Wednesday, 6 Nov 2019 

Amneal Pharmaceuticals Inc ::AMNEAL ENTERS INTO A LICENSING AGREEMENT WITH KASHIV BIOSCIENCES, LLC TO DEVELOP AND COMMERCIALIZE K127 FOR THE TREATMENT OF MYASTHENIA GRAVIS.AMNEAL PHARMACEUTICALS INC - AMNEAL GAINS EXCLUSIVE RIGHTS WITHIN UNITED STATES TO NEW DRUG APPLICATION (NDA) AND COMMERCIALIZATION OF K127.AMNEAL PHARMACEUTICALS - UNDER TERMS KASHIV WILL BE RESPONSIBLE FOR ALL DEVELOPMENT, CLINICAL WORK REQUIRED TO SECURE FDA APPROVAL.AMNEAL PHARMACEUTICALS - KASHIV WILL RECEIVE UPFRONT PAYMENT OF $1.5 MILLION & IS ELIGIBLE TO RECEIVE DEVELOPMENT & REGULATORY MILESTONES OF $16.5 MILLION.  Full Article